Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.
2.
3.

Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer.

Milane L, Duan Z, Amiji M.

PLoS One. 2011;6(9):e24075. doi: 10.1371/journal.pone.0024075. Epub 2011 Sep 8.

4.

Biodistribution and pharmacokinetic analysis of Paclitaxel and ceramide administered in multifunctional polymer-blend nanoparticles in drug resistant breast cancer model.

van Vlerken LE, Duan Z, Little SR, Seiden MV, Amiji MM.

Mol Pharm. 2008 Jul-Aug;5(4):516-26. doi: 10.1021/mp800030k. Epub 2008 Jul 11.

5.

Antibody conjugated PLGA nanoparticles for targeted delivery of paclitaxel palmitate: efficacy and biofate in a lung cancer mouse model.

Karra N, Nassar T, Ripin AN, Schwob O, Borlak J, Benita S.

Small. 2013 Dec 20;9(24):4221-36. doi: 10.1002/smll.201301417. Epub 2013 Jul 21.

PMID:
23873835
6.

Poly(ethylene glycol)-block-poly(ε-caprolactone)-and phospholipid-based stealth nanoparticles with enhanced therapeutic efficacy on murine breast cancer by improved intracellular drug delivery.

He X, Li L, Su H, Zhou D, Song H, Wang L, Jiang X.

Int J Nanomedicine. 2015 Mar 5;10:1791-804. doi: 10.2147/IJN.S75186. eCollection 2015.

7.

Reversal of multidrug resistance by co-delivery of paclitaxel and lonidamine using a TPGS and hyaluronic acid dual-functionalized liposome for cancer treatment.

Assanhou AG, Li W, Zhang L, Xue L, Kong L, Sun H, Mo R, Zhang C.

Biomaterials. 2015 Dec;73:284-95. doi: 10.1016/j.biomaterials.2015.09.022. Epub 2015 Sep 16.

PMID:
26426537
8.

CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer.

Swaminathan SK, Roger E, Toti U, Niu L, Ohlfest JR, Panyam J.

J Control Release. 2013 Nov 10;171(3):280-7. doi: 10.1016/j.jconrel.2013.07.014. Epub 2013 Jul 18.

PMID:
23871962
9.

Role of integrated cancer nanomedicine in overcoming drug resistance.

Iyer AK, Singh A, Ganta S, Amiji MM.

Adv Drug Deliv Rev. 2013 Nov;65(13-14):1784-802. doi: 10.1016/j.addr.2013.07.012. Epub 2013 Jul 21. Review.

PMID:
23880506
11.

The pharmacokinetics of oral lonidamine in breast and lung cancer patients.

Newell DR, Mansi J, Hardy J, Button D, Jenns K, Smith IE, Picollo R, Catanese B.

Semin Oncol. 1991 Apr;18(2 Suppl 4):11-7.

PMID:
2031191
12.

Development of targeted therapy with paclitaxel incorporated into EGF-conjugated nanoparticles.

Shimada T, Ueda M, Jinno H, Chiba N, Wada M, Watanabe J, Ishihara K, Kitagawa Y.

Anticancer Res. 2009 Apr;29(4):1009-14.

13.

Active and passive tumor targeting of a novel poorly soluble cyclin dependent kinase inhibitor, JNJ-7706621.

Danhier F, Ucakar B, Magotteaux N, Brewster ME, Préat V.

Int J Pharm. 2010 Jun 15;392(1-2):20-8. doi: 10.1016/j.ijpharm.2010.03.018. Epub 2010 Mar 11.

PMID:
20226846
14.
15.

A novel paclitaxel-loaded poly(epsilon-caprolactone)/Poloxamer 188 blend nanoparticle overcoming multidrug resistance for cancer treatment.

Zhang Y, Tang L, Sun L, Bao J, Song C, Huang L, Liu K, Tian Y, Tian G, Li Z, Sun H, Mei L.

Acta Biomater. 2010 Jun;6(6):2045-52. doi: 10.1016/j.actbio.2009.11.035. Epub 2009 Dec 5.

PMID:
19969111
16.

Biodistribution and pharmacokinetics of Mad2 siRNA-loaded EGFR-targeted chitosan nanoparticles in cisplatin sensitive and resistant lung cancer models.

Nascimento AV, Gattacceca F, Singh A, Bousbaa H, Ferreira D, Sarmento B, Amiji MM.

Nanomedicine (Lond). 2016 Apr;11(7):767-81. doi: 10.2217/nnm.16.14. Epub 2016 Mar 16.

17.

Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities.

Kirtane AR, Kalscheuer SM, Panyam J.

Adv Drug Deliv Rev. 2013 Nov;65(13-14):1731-47. doi: 10.1016/j.addr.2013.09.001. Epub 2013 Sep 10. Review.

19.

EGFR-targeted gelatin nanoparticles for systemic administration of gemcitabine in an orthotopic pancreatic cancer model.

Singh A, Xu J, Mattheolabakis G, Amiji M.

Nanomedicine. 2016 Apr;12(3):589-600. doi: 10.1016/j.nano.2015.11.010. Epub 2015 Dec 3.

20.

Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance.

Patil Y, Sadhukha T, Ma L, Panyam J.

J Control Release. 2009 May 21;136(1):21-9. doi: 10.1016/j.jconrel.2009.01.021. Epub 2009 Feb 5.

PMID:
19331851

Supplemental Content

Support Center